Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.81
- Piotroski Score 4.00
- Grade Buy
- Symbol (CGEN)
- Company Compugen Ltd.
- Price $1.40
- Changes Percentage (-3.45%)
- Change -$0.05
- Day Low $1.38
- Day High $1.50
- Year High $3.03
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $4.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.18
- Trailing P/E Ratio -11.72
- Forward P/E Ratio -11.72
- P/E Growth -11.72
- Net Income $-18,754,000
Income Statement
Quarterly
Annual
Latest News of CGEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...
The proposed phase two study targets patients with two prior lines of chemotherapy containing platinum. Patients must have received maintenance with Bevacizumab or Parp inhibitors but not suitable for...
By Yahoo! Finance | 1 week ago -
SocGen Leasing Arm Ayvens Said to Draw Blackstone Interest
French car-leasing company Ayvens SA, owned by Societe Generale, is being eyed for takeover by investment firms like Blackstone and industry players like JA Mitsui Leasing. Ayvens has attracted intere...
By Yahoo! Finance | 2 weeks ago -
Chinese stocks could rally 15% as more stimulus spurs a GDP growth spurt next year, SocGen says
Société Générale predicts a potential 5% growth in China's GDP next year due to expected stimulus measures. Recent monetary actions have already led to increased investor optimism, with a forecast...
By Yahoo! Finance | 1 month ago
